Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Lymphoid 2Dermatologic 2

Conditions

Recurrence 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma 2Hodgkin Disease 2Dendritic Cell Sarcoma, Interdigitating 2Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 444Rituximab 401Etoposide 224Vincristine 215Doxorubicin 201Filgrastim 200Prednisone 176Cytarabine 159Radiotherapy 152fludarabine phosphate 147Methotrexate 137Peripheral Blood Stem Cell Transplantation 129Melphalan 127fludarabine 115Busulfan 99Dexamethasone 93Tacrolimus 75Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 71Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 62Cyclosporine 62Bendamustine Hydrochloride 62Lenalidomide 60Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lymphoma × iratumumab × Clear all
NCT00059995 2013-05-30

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
DermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Dendritic Cell Sarcoma, Interdigitating

NCT00298467 2010-04-26

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Bristol-Myers Squibb

Phase 2 Withdrawn
45 enrolled
DermatologicLymphoidSarcoma

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡